{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:20:15Z","timestamp":1777868415748,"version":"3.51.4"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA060231-01"],"award-info":[{"award-number":["R01DA060231-01"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>\n                    This protocol outlines planned methodology for a systematic review and meta-analysis of dopaminergic neuroimaging findings in individuals with opioid use disorder (OUD). Converging evidence across substance use disorders (SUDs) shows dopaminergic dysregulation, including low dopamine D\n                    <jats:sub>2<\/jats:sub>\n                    receptor (D\n                    <jats:sub>2<\/jats:sub>\n                    R) availability and dopamine release, correlating to anhedonia, altered reward processing, impulsivity, and drug-seeking. Opioid use indirectly alters dopamine signaling, with preclinical work showing dopamine D\n                    <jats:sub>2<\/jats:sub>\n                    receptor and transporter (DAT) changes. However, human Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) findings are heterogeneous. Therefore, a systematic synthesis is needed to clarify dopaminergic differences related to chronic opioid exposure and their clinical significance. The proposed review will include peer-reviewed studies of adults with diagnosed OUD using PET or SPECT to assess dopaminergic moieties. Databases searched will include PubMed, Scopus, Web of Science, Google Scholar, and Embase. Two independent reviewers will screen records and assess methodological quality. Screening will occur in two stages (title\/abstract followed by full-text review) using predefined eligibility criteria. Data will be synthesized descriptively and random-effects meta-analyses will be conducted in Review Manager to estimate pooled dopaminergic measures (e.g., D\n                    <jats:sub>2<\/jats:sub>\n                    \/D\n                    <jats:sub>3<\/jats:sub>\n                    receptor availability, DAT availability). Statistical heterogeneity will be evaluated using the I\n                    <jats:sub>2<\/jats:sub>\n                    statistic, and sensitivity analyses will assess the impact of methodological variability (i.e. radiotracer type, abstinence duration). This review protocol was registered to the International Prospective Register for Systematic Reviews (PROSPERO; CRD420251229301). Given the substantial global burden of OUD, systematically investigating its neurobiology will provide important mechanistic insights to support the development of novel pharmacotherapies. Although currently approved medications are available, all act on the \u03bc-opioid receptor (\u03bcOR) and are associated with moderate treatment retention and frequent relapse, generating the need for additional, mechanistically informed therapeutic targets. This will be the first systematic review and meta-analysis exploring dopaminergic measures in humans with OUD, aiming to offer a clearer understanding of how key dopaminergic markers differ between affected individuals and healthy controls, and explore their potential clinical relevance. Insights generated may inform the development of alternative, non-\u03bcOR pharmacological strategies for OUD, including emerging D\n                    <jats:sub>3<\/jats:sub>\n                    -selective therapeutics and \u03ba-opioid receptor modulators with the capacity to indirectly influence dopaminergic system function.\n                  <\/jats:p>","DOI":"10.3389\/fpsyt.2026.1800420","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:54:21Z","timestamp":1777550061000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Protocol for a systematic review and meta-analysis of the relationship between opioid exposure and dopaminergic measures in humans assessed by nuclear medicine imaging"],"prefix":"10.3389","volume":"17","author":[{"given":"Yulia","family":"Shatalov","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine","place":["New Haven, CT, United States"]},{"name":"Connecticut Mental Health Center","place":["New Haven, CT, United States"]},{"name":"Clinical Neuroscience Research Unit, Connecticut Mental Health Center","place":["New Haven, CT, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiago","family":"Paiva Prudente","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine","place":["New Haven, CT, United States"]},{"name":"Connecticut Mental Health Center","place":["New Haven, CT, United States"]},{"name":"Clinical Neuroscience Research Unit, Connecticut Mental Health Center","place":["New Haven, CT, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrique N. P.","family":"Oliva","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine","place":["New Haven, CT, United States"]},{"name":"Connecticut Mental Health Center","place":["New Haven, CT, United States"]},{"name":"Clinical Neuroscience Research Unit, Connecticut Mental Health Center","place":["New Haven, CT, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Shamabadi","sequence":"additional","affiliation":[{"name":"Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences","place":["Tehran, Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc N.","family":"Potenza","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine","place":["New Haven, CT, United States"]},{"name":"Child Study Center, Yale University School of Medicine","place":["New Haven, CT, United States"]},{"name":"Department of Neuroscience, Yale University","place":["New Haven, CT, United States"]},{"name":"Connecticut Council on Problem Gambling","place":["Wethersfield, CT, United States"]},{"name":"Wu Tsai Institute, Yale University","place":["New Haven, CT, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo A.","family":"Angarita","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yale University School of Medicine","place":["New Haven, CT, United States"]},{"name":"Connecticut Mental Health Center","place":["New Haven, CT, United States"]},{"name":"Clinical Neuroscience Research Unit, Connecticut Mental Health Center","place":["New Haven, CT, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: development, challenges and opportunities","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"100052","DOI":"10.1016\/j.dadr.2022.100052","article-title":"What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size","volume":"3","author":"Keyes","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6817a3","article-title":"Drug overdose deaths involving cocaine and psychostimulants with abuse potential - United States, 2003-2017","volume":"68","author":"Kariisa","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6934a1","article-title":"Nonfatal drug and polydrug overdoses treated in emergency departments - 29 states, 2018-2019","volume":"69","author":"Liu","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.2844","article-title":"Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010-2016","volume":"319","author":"Jones","year":"2018","journal-title":"Jama"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.3126","article-title":"Prevention and treatment of opioid misuse and addiction: a review","volume":"76","author":"Volkow","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2019.06.020","article-title":"Medication treatment of opioid use disorder","volume":"87","author":"Bell","year":"2020","journal-title":"Biol Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02627.x","article-title":"Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment","volume":"104","author":"Bell","year":"2009","journal-title":"Addiction"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-015-1314-5","article-title":"Demographic and clinical factors predicting retention in methadone maintenance: results from a\tn Irish cohort","volume":"185","author":"Darker","year":"2016","journal-title":"Ir J Med Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"key":"B11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jsat.2010.03.008","article-title":"Trends in methadone maintenance treatment participation, retention, and compliance to dosing guidelines in British Columbia, Canada: 1996-2006","volume":"39","author":"Nosyk","year":"2010","journal-title":"J Subst Abuse Treat"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)32812-x","article-title":"Comparative effectiveness of extended-release naltrexone versusbuprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicenter, open-label, randomized controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.10.017","article-title":"Multi-center observational study of buprenorphine use in 32 Italian drug addiction centers","volume":"94","author":"Leonardi","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2009.10.006","article-title":"A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction","volume":"30","author":"Veilleux","year":"2010","journal-title":"Clin Psychol Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2005.02.007","article-title":"An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research","volume":"28","author":"Amato","year":"2005","journal-title":"J Subst Abuse Treat"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)32812-x","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicenter, open-label, randomized controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120094","article-title":"Looking beyond the opioid receptor: a desperate need for new treatments for opioid use disorder","volume":"432","author":"Lee","year":"2022","journal-title":"J Neurol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01590-8","article-title":"Effects of selective dopamine D3 receptor partial agonist\/antagonists on oxycodone self-administration and antinociception in monkeys","volume":"48","author":"Woodlief","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/adb.13241","article-title":"Intermittent access to oxycodone decreases dopamine uptake in the nucleus accumbens core during abstinence","volume":"27","author":"Samson","year":"2022","journal-title":"Addict Biol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neuropharm.2018.08.016","article-title":"Genetic deletion of the dopamine D3 receptor increases vulnerabilityto heroin in mice","volume":"141","author":"Zhan","year":"2018","journal-title":"Neuropharmacology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/s0169-328x(02)00671-x","article-title":"Elevated D3 dopamine receptor mRNA in dopaminergic and dopaminoceptive regions of the rat brain in response to morphine","volume":"111","author":"Spangler","year":"2003","journal-title":"Mol Brain Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2024.05.020","article-title":"Presynaptic and postsynaptic mesolimbic dopamine D(3) receptors play distinct roles in cocaine versus opioid reward in mice","volume":"96","author":"Xi","year":"2024","journal-title":"Biol Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","first-page":"110917","DOI":"10.1016\/j.brainresbull.2024.110917","article-title":"The impact of chronic fentanyl administration on the cerebral cortex in mice: molecular and histological effects","volume":"209","author":"Alzu'bi","year":"2024","journal-title":"Brain Res Bull"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fnsyn.2019.00035","article-title":"Morphine differentially alters the synaptic and intrinsic properties of D1R- and D2R-expressing medium spiny neurons in the nucleus accumbens","volume":"11","author":"McDevitt","year":"2019","journal-title":"Front Synaptic Neurosci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00631-1","article-title":"Intermittent morphine treatment causes long-term desensitization of functional dopamine D2 receptors in rat striatum","volume":"294","author":"Nestby","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/syn.21755","article-title":"Changes in dopamine transporter binding in nucleus accumbens following chronic self-administration cocaine: heroin combinations","volume":"68","author":"Pattison","year":"2014","journal-title":"Synapse"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2012.07738.x","article-title":"Differential regulation of accumbal dopamine transmission in rats following cocaine, heroin and speedball self-administration","volume":"122","author":"Pattison","year":"2012","journal-title":"J Neurochem"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.2000.00063.x","article-title":"Increased rewarding properties of morphine in dopamine-transporter knockout mice","volume":"12","author":"Spielewoy","year":"2000","journal-title":"Eur J Neurosci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s0893-133x(96)00184-4","article-title":"Dopamine D2 receptor availability in opiate-dependent subjectsbefore and after naloxone-precipitated withdrawal","volume":"16","author":"Wang","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.08.024","article-title":"Deficits in dopamine D(2) receptors and presynaptic dopamine in heroin dependence: commonalities and differences with other types of addiction","volume":"71","author":"Martinez","year":"2012","journal-title":"Biol Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.07020352","article-title":"Association of low striatal dopamine D 2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse","volume":"165","author":"Fehr","year":"2008","journal-title":"Am J Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300420","article-title":"Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior","volume":"29","author":"Martinez","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2010.10050748","article-title":"Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment","volume":"168","author":"Martinez","year":"2011","journal-title":"Am J Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.04.044","article-title":"Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum","volume":"58","author":"Martinez","year":"2005","journal-title":"Biol Psychiatry"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.12.2015","article-title":"Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex","volume":"1","author":"Volkow","year":"2003","journal-title":"Focus"},{"key":"B37","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1001\/archpsyc.63.9.999","article-title":"High levels of dopamine D2 receptors in unaffected members of alcoholic families: possible protective factors","volume":"63","author":"Volkow","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/386830a0","article-title":"Decreased striatal dopaminergic responsivity indetoxified cocaine abusers","volume":"386","author":"Nd","year":"1997","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001507","article-title":"Dopamine in drug abuse and addiction: results of imaging studies and treatment implications","volume":"64","author":"Volkow","year":"2007","journal-title":"Arch Neurol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.10.1783","article-title":"Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving","volume":"161","author":"Heinz","year":"2004","journal-title":"Am J Psychiatry"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1523\/jneurosci.3371-07.2007","article-title":"Profound decreases in dopamine release in striatum in detoxified alcoholics: possible orbitofrontal involvement","volume":"27","author":"Volkow","year":"2007","journal-title":"J Neurosci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/386830a0","article-title":"Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects","volume":"386","author":"Volkow","year":"1997","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1523\/jneurosci.3765-09.2009","article-title":"Striatal dopamine d2\/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity","volume":"29","author":"Lee","year":"2009","journal-title":"J Neurosci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.2001.tb00157.x","article-title":"Is increased D2 receptor availability associated with response to stimulant medication in ADHD","volume":"43","author":"Ilgin","year":"2001","journal-title":"Dev Med Child Neurol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyy030","article-title":"Ventral striatal D2\/3 receptor availability is associated with impulsive choice behavior as well as limbic corticostriatal connectivity","volume":"21","author":"Barlow","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.9.1440","article-title":"Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels","volume":"156","author":"Volkow","year":"1999","journal-title":"Am J Psychiatry"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.pscychresns.2023.111660","article-title":"Striatal dopamine in anhedonia: a simultaneous [(11)C]raclopride positron emission tomography and functional magnetic resonance imaging investigation","volume":"333","author":"Phillips","year":"2023","journal-title":"Psychiatry Res Neuroimaging"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2009.110","article-title":"Neurocircuitry of addiction","volume":"35","author":"Koob","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/s0893-133x(96)00184-4","article-title":"Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal","volume":"16","author":"Wang","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.08.024","article-title":"Deficits in dopamine D2 receptors and presynaptic dopamine in heroin dependence: Commonalities and differences with other types of addiction","volume":"71","author":"Martinez","year":"2012","journal-title":"Biol Psychiatry"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2008.522","article-title":"Responsiveness to drug cues and natural rewards in opiate addiction: Associations with later heroin use","volume":"66","author":"Lubman","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3565(25)22405-3","article-title":"Dopamine D2 and D3 receptors inhibit dopamine release","volume":"270","author":"Tang","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"B53","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.neubiorev.2020.04.024","article-title":"Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges","volume":"114","author":"Galaj","year":"2020","journal-title":"Neurosci Biobehav Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2019.00292","article-title":"Dopamine D3 receptor antagonism reverses the escalation of oxycodone self-administration and decreases withdrawal-induced hyperalgesia and irritability-like behavior in oxycodone-dependent heterogeneous stock rats","volume":"13","author":"de Guglielmo","year":"2020","journal-title":"Front Behav Neurosci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00057","article-title":"Crosstalk between kappa opioid and dopamine systems in compulsive behaviors","volume":"11","author":"Escobar","year":"2020","journal-title":"Front Pharmacol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.brainres.2018.09.023","article-title":"Dynorphin\/kappa-opioid receptor control of dopamine dynamics: Implications for negative affective states and psychiatric disorders","volume":"1713","author":"Tejeda","year":"2019","journal-title":"Brain Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2024.105713","article-title":"A review of the kappa opioid receptor system in opioid use","volume":"162","author":"Cayir","year":"2024","journal-title":"Neurosci Biobehav Rev"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-025-02226-9","article-title":"Kappa opioid receptor control of motivated behavior revisited","volume":"51","author":"Farahbakhsh","year":"2026","journal-title":"Neuropsychopharmacology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyu119","article-title":"Low dopamine D2\/D3 receptor availability is associated with steep discounting of delayed rewards in methamphetamine dependence","volume":"18","author":"Ballard","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"8888","DOI":"10.1523\/jneurosci.6028-09.2010","article-title":"Dopamine, time, and impulsivity in humans","volume":"30","author":"Pine","year":"2010","journal-title":"J Neurosci"},{"key":"B61","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.neuropharm.2013.06.031","article-title":"Imaging addiction: D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity","author":"Trifilieff","year":"2014","journal-title":"Neuropharmacology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2025.111389","article-title":"Dopamine D3 receptor in the nucleus accumbens modulates opioid taking and seeking in mice","volume":"139","author":"Yang","year":"2025","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"B63","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neuropharm.2018.08.016","article-title":"Genetic deletion of the dopamine D3 receptor increases vulnerability to heroin in mice","volume":"141","author":"Zhan","year":"2018","journal-title":"Neuropharmacology"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/s0893-133x(00)00209-8","article-title":"Striatal dopaminergic and serotonergic markers in human heroin users","volume":"24","author":"Kish","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1523\/jneurosci.2398-07.2007","article-title":"Heroin abuse is characterized by discrete mesolimbic dopamine and opioid abnormalities and exaggerated nuclear receptor-related 1 transcriptional decline with age","volume":"27","author":"Horvath","year":"2007","journal-title":"J Neurosci"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-018-0191-9","article-title":"Effects of sedative drug use on the dopamine system: A systematic review and meta-analysis of in vivo neuroimaging studies","volume":"44","author":"Kamp","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"B67","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1192\/bjp.bp.107.041228","article-title":"Brain dopamine response in human opioid addiction","volume":"193","author":"Daglish","year":"2008","journal-title":"Br J Psychiatry"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12073","article-title":"Investigating expectation and reward in human opioid addiction with [(11) C]raclopride PET","volume":"19","author":"Watson","year":"2014","journal-title":"Addict Biol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"Bmj"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.31222\/osf.io\/v7gm2","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2024.108602","article-title":"A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E)","volume":"186","author":"Higgins","year":"2024","journal-title":"Environ Int"},{"key":"B72","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.ad","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Bmj"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1800420\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:54:22Z","timestamp":1777550062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1800420\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":73,"alternative-id":["10.3389\/fpsyt.2026.1800420"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1800420","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"article-number":"1800420"}}